NAFDAC Legal Mandate: The Two Statutes Behind Nigerian Device Regulation

1. Key takeaways

The legal authority for medical device regulation in Nigeria does not rest on a single statute. It rests on two statutes stacked together, and understanding both is the first step in any Nigerian regulatory assessment:

• The National Agency for Food and Drug Administration and Control Act (Cap. N1, LFN 2004) — establishes NAFDAC and empowers it to make regulations; the regulation-making provision is section 30;
• The Food, Drugs and Related Products (Registration, Etc.) Act (Cap. F33, LFN 2004) — establishes the registration regime for regulated products; the enabling provision is section 12.

The cover page of the current device-specific instrument, the NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024 (S.I. No. 42 of 2024), states expressly that the Regulations were made by the Governing Council of NAFDAC with the approval of the Minister of Health, pursuant to section 30 of Cap. N1, section 12 of Cap. F33 and all other enabling powers. The maker of the instrument is the Governing Council, not the Minister personally.

For device companies, this chain of authority determines three practical things. First, unregistered means unlawful, because the registration regime of Cap. F33 is reinforced by regulation 47 of the 2024 Regulations. Second, guidelines can impose technical obligations, since the registration guidelines state expressly that they are made under Cap. N1. Third, the benchmark for any legality review in a dispute is these two statutes, not the guidelines.

2. Legal basis

3. Expert insights

Insight 1: the two enabling statutes have distinct roles, and neither is dispensable.

Cap. N1 answers the question of who has the power to set the rules: it confers institutional competence on NAFDAC and a regulation-making power through section 30. Cap. F33 answers the question of what the rules govern: registration, labelling and advertisement of regulated products. The cover page of S.I. No. 42 of 2024 cites both statutes precisely because a single regulation draws on both types of power. When GRZAN assesses the legality of the new Nigerian framework, it verifies that both enabling provisions remain in force.

Insight 2: the maker is the Governing Council with ministerial approval, not the Minister directly.

The instrument states that it was made by the Governing Council of NAFDAC with the approval of the Minister of Health (with the approval of the Minister of Health). This detail matters in two practical ways. The interpretation and amendment of the Regulations follow the Governing Council route. And when a company applies for an exemption or seeks a policy clarification, the receiving and responding level is NAFDAC itself, not the Federal Ministry of Health.

Insight 3: guidelines are not statutes, but their binding source of authority is written clearly.

Take the IVD dossier compilation guideline as an example. Its Scope section states: “These Guidelines have been developed in pursuance to the NAFDAC Act Cap N1, LFN, 2004”. Nigerian guidelines are therefore not optional reference material. A dossier not compiled in line with the guideline can directly trigger rejection, serious evaluation delays, or suspension of the evaluation procedure — the guideline text itself lists these possible outcomes.

Insight 4: compared with other African markets already covered, Nigeria uses a three-layer law–regulation–guideline structure.

Tanzania operates a three-layer structure of an Act (Cap. 219), regulations (GN. No. 315) and consolidated guidelines. Kenya has long relied mainly on guidelines together with the Pharmacy and Poisons Act. Nigeria completed the dedicated device regulation layer in 2024. The practical difference between the layers is direct: the regulation layer carries penalties and mandatory registration provisions; the guideline layer does not.

Insight 5: the year 2004 reflects the revised edition of the laws, not outdated rules.

Both Cap. N1 and Cap. F33 are 2004 revised editions of the Laws of the Federation of Nigeria (LFN 2004). This is the edition year of the revised laws, not evidence that the text has never been updated. When citing, companies should write “Cap. N1, LFN 2004” and never “the 2004 NAFDAC Act” — the latter phrasing can be misread as meaning the Act was enacted in 2004.

4. Practical recommendations

1. Record Nigerian entries in the internal regulatory ledger under the three layers of law, regulation and guideline, each tagged with its number and effective date, to avoid conflating the layers.
2. Cite in full form plus number: Cap. N1, LFN 2004, section 30; Cap. F33, LFN 2004, section 12; S.I. No. 42 of 2024.
3. Do not treat the guidelines as soft reference material — the NAFDAC guidelines state expressly that they are made under Cap. N1, and non-compliance can trigger procedural consequences.
4. Direct exemption and policy-clarification communications to NAFDAC within the Governing Council authorization system, rather than applying directly to the Ministry of Health.
5. Track the gazettal progress of the 2025 draft regulations: once gazetted, they will add statutory provisions on clinical investigations, quality systems and vigilance on top of the current Regulations.

5. Verification checklist

• □ Confirmed the citations of the two statutes: Cap. N1, section 30 and Cap. F33, section 12.
• □ Confirmed that the current dedicated instrument is S.I. No. 42 of 2024, commencing 16 October 2024.
• □ Registered the regulations and the guidelines as separate layers in the internal ledger, without conflation.
• □ Confirmed the reference number and effective date of each guideline relied upon (for example, VBM-R&RA-GDL-001-01, effective 2025-04-10).
• □ Established a tracking mechanism for the gazettal status of the 2025 draft regulations.
• □ Ensured that external documents contain no misleading phrasing such as “the 2004 NAFDAC Act”.

Regulatory information verified as of 29 October 2026. The provisions cited were checked against the regulation text published on the NAFDAC website (S.I. No. 42 of 2024, cover page and regulation 52) and the guideline texts (VBM-R&RA-GDL-001-01 §1.2; VBM-R&RA-GDL-005-01, Scope). Updates are re-checked whenever the regulations change.

GRZAN support for the Nigerian market. GRZAN provides NAFDAC registration and compliance support for the Nigerian market, with local resources covering coordination with licensed importers and authorized representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Service capabilities cover classification assessment, registration pathway selection, technical documentation to the IMDRF ToC, CMFS and legalization support, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, variation management and certificate renewal. Contact: info@grzanglobal.com.